Cadila Healthcare receives approval for Warfarin tablets from US FDA

Mumbai, June 1 (UNI) Cadila Healthcare today announced that it received approval from the US FDA to market Warfarin Tablets in different strengths of 1 mg, 2 mg, 2.5 mg, 3 mg, 4mg, 5mg 6mg, 7.5 mg and 10 mg.

The drug, an anti-coagulant, falls in the cardiovascular segment.

Informing the BSE, the company said the Group plans to launch the product within a month's time. The branded sales of the product in 2005 were reported to be over dollar 210 mn. With this, the group now has a total of 14 approvals.

The Group is likely to have considerable competitive advantage in this product as it will be sourcing the API from its own US FDA approved manufacturing facility at Dabhasa.

UNI SN MJ AG1823